BK7508 Pharmaceutical Companies
Market Closed 07-05 16:00:00 AEST
1,006.48
+8.35
+0.84%
High
1,007.14
Low
996.87
Vol
58.13M
Open
998.06
D1 Closing
998.13
Amplitude
1.03%
Mkt Cap
0.00
Tradable Cap
0.00
Total Shares
0.00
T/O
159.10M
T/O Rate
--
Tradable Shares
0.00
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership
Simply Wall St. · 07-05 21:05
Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership
Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide
Small Caps · 07-05 12:35
Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide
BUZZ-Australia's Clinuvel Pharmaceuticals soars on positive study results
Reuters · 07-05 12:09
BUZZ-Australia's Clinuvel Pharmaceuticals soars on positive study results
Brokers name 3 ASX shares to buy now
MotleyFool · 07-05 12:05
Brokers name 3 ASX shares to buy now
Emerald Resources And Two More ASX Growth Companies With High Insider Ownership
Simply Wall St. · 07-05 11:35
Emerald Resources And Two More ASX Growth Companies With High Insider Ownership
ASX Market Update: ASX Up, Healthcare Sector Leads with Clinuvel’s Strong Performance | 5 July 2024
The Market Herald · 07-05 11:24
ASX Market Update: ASX Up, Healthcare Sector Leads with Clinuvel’s Strong Performance | 5 July 2024
Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher
MotleyFool · 07-05 10:35
Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher
Why is this ASX 300 healthcare stock surging 12% today?
MotleyFool · 07-05 08:45
Why is this ASX 300 healthcare stock surging 12% today?
Those who invested in CSL (ASX:CSL) five years ago are up 42%
Simply Wall St. · 07-05 05:21
Those who invested in CSL (ASX:CSL) five years ago are up 42%
Favourable Signals For Starpharma Holdings: Numerous Insiders Acquired Stock
Simply Wall St. · 07-05 04:42
Favourable Signals For Starpharma Holdings: Numerous Insiders Acquired Stock
What happened with the CSL share price in FY 2024?
MotleyFool · 07-05 03:30
What happened with the CSL share price in FY 2024?
The best ASX 200 shares to buy when interest rates fall
MotleyFool · 07-05 03:00
The best ASX 200 shares to buy when interest rates fall
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
GlobeNewswire · 07-04 15:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Zelira Therapeutics Receives $1.4 Million Unsecured Loan from Chairman
MT Newswires Live · 07-04 13:29
Zelira Therapeutics Receives $1.4 Million Unsecured Loan from Chairman
Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%
MT Newswires Live · 07-04 11:55
Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%
Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today
MotleyFool · 07-04 10:55
Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today
Considering AFIC shares? Here's what you're buying
MotleyFool · 07-04 09:52
Considering AFIC shares? Here's what you're buying
Stocks of the Hour: Arafura Rare Earths, Superior Resources, Aeris Resources
Informed Investor · 07-04 09:50
Stocks of the Hour: Arafura Rare Earths, Superior Resources, Aeris Resources
CSL Offering Attractive Entry Point -- Market Talk
Dow Jones · 07-04 09:32
CSL Offering Attractive Entry Point -- Market Talk
Load more
Introduction
Company Name.
BK7508
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":1006.482,"timestamp":1720159199909,"preClose":998.1308,"halted":0,"volume":58126917,"delay":0,"changeRate":0.008367,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":8.351196,"latestTime":"07-05 16:00:00 AEST","open":998.06177,"high":1007.14435,"low":996.87067,"amount":159101268,"amplitude":0.010293,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1720396800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1720137600000,1720159200000]],"turnoverRate":0.001502,"increases":18,"decrements":13,"flats":16,"marketCap":156123691827.5,"floatMarketCap":153705582467.4375},"requestUrl":"/m/hq/s/BK7508","defaultTab":"news","newsList":[{"id":"2449298372","title":"Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2449298372","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449298372?lang=en_us&edition=fundamental","pubTime":"2024-07-05 21:05","pubTimestamp":1720184728,"startTime":"0","endTime":"0","summary":"As global markets navigate through a period of relative calm with anticipation for upcoming earnings reports and key economic indicators, investors continue to assess the landscape for robust investment opportunities. In this environment, growth companies with high insider ownership can be particularly compelling, as substantial insider stakes often signal confidence in the company's future prospects from those who know it best.Click here to see the full list of 1450 stocks from our Fast Growing Companies With High Insider Ownership screener.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that specializes in developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders across Australia, Europe, the U.S., and Switzerland, with a market capitalization of approximately A$0.76 billion.Navigate through the intricacies of Clinuvel Pharmaceuticals with our comprehensive analyst estimates report here.According our valua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clinuvel-pharmaceuticals-leads-three-high-130528542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CTT.AU","BK7049","HHR.AU","BK7067","BK7021","BK7142","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2449233869","title":"Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2449233869","media":"Small Caps","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449233869?lang=en_us&edition=fundamental","pubTime":"2024-07-05 12:35","pubTimestamp":1720154142,"startTime":"0","endTime":"0","summary":"Specialty pharmaceutical group Clinuvel Pharmaceuticals has received promising outcomes from the final set of results from a study evaluating the DNA-repair capacity of its afamelanotide candidate.For the general population, and specifically for individuals with fair skin types who sunburn easily, the results indicate that afamelanotide can reduce oxidative damage and inflammatory reactions after sun exposure and skin damage.The study on the skin of healthy volunteers exposed to ultraviolet radiation was conducted at Salford Royal Hospital in Manchester, with afamelanotide dosing found to lead to a reduction in differentially expressed genes in the skin.“The significance of these results evaluating the use of afamelanotide in reducing oxidative and inflammatory damage caused by UV is high for those at high risk of solar damage, sunburn and skin cancers, hence we will repeat and confirm these results in a final study.”The study analysed biopsies from seven patients with fair skin typ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/07/Clinuvel-ASX-CUV-afamelanotide-DNR-repair.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/07/Clinuvel-ASX-CUV-afamelanotide-DNR-repair.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/clinuvel-breakthrough-uv-damage-skin-dna-repair-study-afamelanotide/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4139","DNA","BK7067","ODD","BK4109","BK7508","CUV.AU","BK4183"],"gpt_icon":0},{"id":"2449928232","title":"BUZZ-Australia's Clinuvel Pharmaceuticals soars on positive study results","url":"https://stock-news.laohu8.com/highlight/detail?id=2449928232","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449928232?lang=en_us&edition=fundamental","pubTime":"2024-07-05 12:09","pubTimestamp":1720152547,"startTime":"0","endTime":"0","summary":"** Shares of Clinuvel Pharmaceuticals rise as much as 16.7% to A$17.710, posting their biggest intraday pct jump since Aug 31, 2022 ** Stock hits highest level since Dec. 11, 2023 ** Pharmaceutical co announces results of its afamelanotide study evaluating DNA-repair capacity of afamelanotide on skin of healthy volunteers exposed to UV radiation ** Says results shows afamelanotide can reduce oxidative damage and inflammatory reactions after sun exposure and skin damage ** Says study shows afamelanotide assists DNA repair after UV damage ** Stock down 5.2% YTD as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","XAO.AU","XKO.AU","BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2449280917","title":"Brokers name 3 ASX shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2449280917","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449280917?lang=en_us&edition=fundamental","pubTime":"2024-07-05 12:05","pubTimestamp":1720152348,"startTime":"0","endTime":"0","summary":"It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summaris","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/05/brokers-name-3-asx-shares-to-buy-now-77/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7034","PMV.AU","BK7511","BK4504","BK7029","LU1162221912.USD","LU0971096721.USD","LU0320765646.SGD","BK7021","LU1363072403.SGD","BK7501","LU0106831901.USD","BK7067","IE00BKVL7J92.USD","BK7153","LU0098860793.USD","MYR.AU","BK4581","LU1989772923.USD","SUN.AU","IE00BZ1G4Q59.USD","BK4585","LU1074936037.SGD","LU1989772840.SGD","BK4588","IAG.AU","LU1668664300.SGD","BK4534","BK7508","CSL.AU","BK4127"],"gpt_icon":0},{"id":"2449284943","title":"Emerald Resources And Two More ASX Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2449284943","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449284943?lang=en_us&edition=fundamental","pubTime":"2024-07-05 11:35","pubTimestamp":1720150515,"startTime":"0","endTime":"0","summary":"Amidst a fluctuating Australian market where the ASX200 has seen minor declines and sectors like Healthcare show resilience, investors continue to navigate through mixed signals. In such a landscape, growth companies with high insider ownership can offer a unique appeal, as these insiders often have a vested interest in the company's success, aligning their goals closely with those of shareholders.Top 10 Growth Companies With High Insider Ownership In Australia. Emerald Resources is positioned for robust growth with earnings expected to increase by 23.2% annually, outpacing the Australian market's average of 13.1%. Despite a past year's earnings surge of 53.4%, shareholder dilution has occurred. Looking ahead, Emerald's revenue growth forecast at 18.6% yearly also exceeds the market expectation of 5.2%. Additionally, its Return on Equity is projected to reach an impressive 20.7% in three years, indicating strong profitability and management efficiency.Operations: The company generates ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emerald-resources-two-more-asx-033515901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","C79.AU","XJO.AU","BK7021","BK7508","BIO.AU","BK7016","BK7070","EMR.AU","XAO.AU","XKO.AU","CCA.AU","CTT.AU","BK7095","BK7142","BK7104","BK7158","PLT.AU","BK7504","HGO.AU","BK7064","DUG.AU","MIN.AU","FLT.AU","BK7111","BK7507","LTR.AU","HHR.AU","ACR.AU","BK7033","BK7093","BK7049"],"gpt_icon":0},{"id":"2449878782","title":"ASX Market Update: ASX Up, Healthcare Sector Leads with Clinuvel’s Strong Performance | 5 July 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2449878782","media":"The Market Herald","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449878782?lang=en_us&edition=fundamental","pubTime":"2024-07-05 11:24","pubTimestamp":1720149840,"startTime":"0","endTime":"0","summary":"The ASX200 was down 0.15% in lunchtime trades.Healthcare was in front, up 0.52% – partially driven by strong results from Clinuvel.CLINUVEL Pharmaceuticals is up around 15% on results from a study evaluating the DNA-repair capacity of afamelanotide on skin of healthy volunteers exposed to ultraviolet radiation.Two months on from receiving a $160 million contract from the WA government to take on the Collie battery project,Southern Cross Eletrcial Egineering has announced it has added another $50 million to the value of the project, with the awarding of a battery storage system from Synergy.Red Hill Minerals has signed a conditional binding Heads of Agreement with Peel Far West Pty, a subsidiary of ASX-listed Peel Mining , to explore the Curnamona Project in NSW. This agreement allows Red Hill to earn a 75% interest by investing $6.5 million in exploration over five years.Auric Mining shot up 7.5% after it announced it expects to generate $3 million revenue in Q3, driven by $2 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-asx-up-healthcare-sector-leads-with-clinuvels-strong-performance-5-july-2024-2024-07-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["AWJ.AU","BK7055","BK4137","PEX.AU","BK7104","BK7067","SXE.AU","BK7508","RHI.AU","BK7095","CUV.AU","BK7129","HCSG","BK7110"],"gpt_icon":0},{"id":"2449289758","title":"Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2449289758","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449289758?lang=en_us&edition=fundamental","pubTime":"2024-07-05 10:35","pubTimestamp":1720146937,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) appears to have run out of steam on Friday. In afternoon trade, the benchmark index is down slightly to 7,824 points. Four ASX shares that are not letting that hold them","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/05/why-clinuvel-guzman-y-gomez-magellan-and-sandfire-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CUV.AU","BK7062","BK7508","SFR.AU","MFG.AU","BK7507","GYG.AU","XJO.AU","BK7110","BK7137","BK7067","BK7506"],"gpt_icon":0},{"id":"2449401231","title":"Why is this ASX 300 healthcare stock surging 12% today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2449401231","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449401231?lang=en_us&edition=fundamental","pubTime":"2024-07-05 08:45","pubTimestamp":1720140326,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals Limited shares are having a strong finish to the week. In morning trade, the ASX 300 healthcare stock is up a sizeable 12% to $17.00. Why is this ASX 300 healthcare stock rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/05/why-is-this-asx-300-healthcare-stock-surging-12-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2449472796","title":"Those who invested in CSL (ASX:CSL) five years ago are up 42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449472796","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449472796?lang=en_us&edition=fundamental","pubTime":"2024-07-05 05:21","pubTimestamp":1720128095,"startTime":"0","endTime":"0","summary":"Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. To wit, the CSL share price has climbed 34% in five years, easily topping the market return of 16% . On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 11%, including dividends.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.During five years of share price growth, CSL achieved compound earnings per share growth of 5.1% per year. This EPS growth is reasonably close to the 6% average annual","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ce0us6EzzGKhRjeO9LQALg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3e36e0d50c325cc3cc49bc90313ca51d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ce0us6EzzGKhRjeO9LQALg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3e36e0d50c325cc3cc49bc90313ca51d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-csl-asx-csl-212135711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["SGXZ23171101.USD","BK7067","CSL.AU","BK4086","BK7511","SG9999004303.SGD","BK7501","LU1169589451.USD","BK7508","LU1169590202.USD","CSL"],"gpt_icon":0},{"id":"2449012286","title":"Favourable Signals For Starpharma Holdings: Numerous Insiders Acquired Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2449012286","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449012286?lang=en_us&edition=fundamental","pubTime":"2024-07-05 04:42","pubTimestamp":1720125729,"startTime":"0","endTime":"0","summary":"Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/favourable-signals-for-starpharma-holdings-numerous-insiders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7501","SPL.AU","BK7508"],"gpt_icon":0},{"id":"2449479169","title":"What happened with the CSL share price in FY 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2449479169","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449479169?lang=en_us&edition=fundamental","pubTime":"2024-07-05 03:30","pubTimestamp":1720121400,"startTime":"0","endTime":"0","summary":"The CSL Ltd (ASX: CSL) share price couldn't quite match the gains posted by the S&P/ASX 200 Index(ASX: XJO) in the financial year we just said goodbye to. Shares in the ASX 200 biotech stock closed ou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/05/what-happened-with-the-csl-share-price-in-fy-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4157","BK7508","BK7095","BK7506","BK7511","BK7501","CSL","SG9999004303.SGD","XJO.AU","CSL.AU","LU1169590202.USD","AMI.AU","BK7067","SGXZ23171101.USD","BK4086","BK4183","LU1169589451.USD","MACE"],"gpt_icon":0},{"id":"2449764134","title":"The best ASX 200 shares to buy when interest rates fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2449764134","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449764134?lang=en_us&edition=fundamental","pubTime":"2024-07-05 03:00","pubTimestamp":1720119600,"startTime":"0","endTime":"0","summary":"While it is looking like there may yet be one more interest rate hike from the Reserve Bank of Australia, it won't be long until rates then start to ease. For example, according to the Westpac Banking Corp economics team, it is forecasting the cash rate to fall from 4.35% today to 3.1% by the end of 2025. In light of this, analysts at Bell Potter think investors should be preparing their portfolios for when interest rates start to fall. Particularly given that US interest rates may start falling earlier and could put a rocket under global share markets. But which ASX 200 shares should investors buy?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/05/the-best-asx-200-shares-to-buy-when-interest-rates-fall/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TCL.AU","BK7090","CSL.AU","JHX","BK7067","BK4011","BK7044","XAO.AU","XKO.AU","WBC.AU","BK7135","BK7511","BK7501","JHX.AU","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2448418204","title":"CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2448418204","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448418204?lang=en_us&edition=fundamental","pubTime":"2024-07-04 15:00","pubTimestamp":1720076400,"startTime":"0","endTime":"0","summary":"MARBURG, Germany, July 04, 2024 -- Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe.HEMGENIX is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX . It is used in adults without a history of Factor IX inhibitors.1. Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX offers a one-time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4. Hemophilia B is a life-threatening rare disease. People with the conditi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AVZpl0kMa5tQ4V_slmXBvw--~B/aD00Njg7dz0yMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/13dfcd0deaf0ea858983506c36941eef","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AVZpl0kMa5tQ4V_slmXBvw--~B/aD00Njg7dz0yMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/13dfcd0deaf0ea858983506c36941eef"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/csl-behring-announces-first-two-070000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","BK4110","ABR","TGA","BK4201","ABR.AU","BK7511","BK7501","BK7504","CSL.AU","EC","BK4213","SGXZ23171101.USD","BK4086","BK7508","BK7095","CSL","SG9999004303.SGD","BK7001","TGA.AU","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2448491866","title":"Zelira Therapeutics Receives $1.4 Million Unsecured Loan from Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2448491866","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448491866?lang=en_us&edition=fundamental","pubTime":"2024-07-04 13:29","pubTimestamp":1720070977,"startTime":"0","endTime":"0","summary":"Zelira Therapeutics received a $1.4 million working capital loan from Chairman Osagie Imasogie, according to a Thursday filing with the Australian bourse.The unsecured debt will become a convertible loan bond at $0.40 per share, subject to shareholder approval. This represents a more than 100% premium to the closing price on June 28, based on a July 1 filing.Funds are for the advancement of the HOPE special purpose vehicle clinical trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7502","LENZ","BK7508","BK4139","ZLD.AU"],"gpt_icon":0},{"id":"2448498752","title":"Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448498752","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448498752?lang=en_us&edition=fundamental","pubTime":"2024-07-04 11:55","pubTimestamp":1720065351,"startTime":"0","endTime":"0","summary":"Dimerix plans to recruit adolescent patients between the ages of 12 and 17, for the ACTION3 clinical trial of its kidney drug DMX-200, the biopharmaceutical company said in a Thursday filing with the Australian bourse.The patients with focal segmental glomerulosclerosis will be dosed with 120mg of the drug orally and twice daily, the filing said.Shares of Dimerix fell over 7% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2448985924","title":"Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2448985924","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448985924?lang=en_us&edition=fundamental","pubTime":"2024-07-04 10:55","pubTimestamp":1720061718,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,818.3 points. Four ASX shares that have failed to fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/04/why-dimerix-new-hope-pro-medicus-and-west-african-resources-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7083","BK7104","BK7094","DXB.AU","XJO.AU","NHC.AU","WAF.AU","BK7067","BK7506","PME.AU","HOPE","BK7508","BK4211","BK7501"],"gpt_icon":0},{"id":"2448691814","title":"Considering AFIC shares? Here's what you're buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2448691814","media":"MotleyFool","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448691814?lang=en_us&edition=fundamental","pubTime":"2024-07-04 09:52","pubTimestamp":1720057953,"startTime":"0","endTime":"0","summary":"Buying Australian Foundation Investment Co Ltd shares comes with a lot of different underlying investments. Although an individual company, a listed investment company invests in other shares for shareholders. Some LICs invest in areas like Asian shares, global shares, or ASX shares. AFIC is one of the largest and oldest LICs in Australia and primarily invests in ASX shares. It aims to provide shareholders with \"attractive investment returns through access to a growing stream of fully franked dividends and enhancement of capital invested over the medium to long term.\" Which ASX shares is AFIC invested in?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/07/04/considering-afic-shares-heres-what-youre-buying/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WBC.AU","MQG.AU","BK7145","BK7042","BK7095","XAO.AU","BK7002","XJO.AU","BK7511","BK7067","TCL.AU","BK7090","BHP.AU","WOW.AU","TLS.AU","BK7155","BK7507","WDS.AU","ANZ.AU","BK7135","XKO.AU","BK7041","BK7099","BK7510","NAB.AU","LIC.AU","BK7503","BK7040","BK7046","JHX.AU","CSL.AU","CBA.AU","CAR.AU","GMG.AU","RIO.AU","WES.AU","BK7501","BK7142","BK7508","BK7044","BK7153","AFI.AU"],"gpt_icon":0},{"id":"2448841644","title":"Stocks of the Hour: Arafura Rare Earths, Superior Resources, Aeris Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2448841644","media":"Informed Investor","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448841644?lang=en_us&edition=fundamental","pubTime":"2024-07-04 09:50","pubTimestamp":1720057838,"startTime":"0","endTime":"0","summary":"A snapshot of the stocks on the move, featuring Arafura Rare Earths (ASX:ARU), Superior Resources (ASX:SPQ) and Aeris Resources (ASX:AIS).","market":null,"thumbnail":"https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/1ec54c10ee4b7c733ca7888881ed156825ae52e5.jpg","type":0,"news_type":0,"thumbnails":["https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/1ec54c10ee4b7c733ca7888881ed156825ae52e5.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finnewsnetwork.com.au/archives/finance_news_network470087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","ARU.AU","SPQ.AU","AIS.AU","BK7095","IMC.AU","BK7110"],"gpt_icon":0},{"id":"2448463784","title":"CSL Offering Attractive Entry Point -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2448463784","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448463784?lang=en_us&edition=fundamental","pubTime":"2024-07-04 09:32","pubTimestamp":1720056720,"startTime":"0","endTime":"0","summary":"0132 GMT - CSL is offering prospective investors an attractive entry point ahead of expected annual EPS growth of 15% over the next five years, Macquarie analysts write in a note. They tell clients that they expect the Australian vaccine maker's biotherapeutics division to drive earnings growth. Their net profit forecast for fiscal 2026 is about 4% higher than the average analyst forecast, and about 7% higher for each of the next two fiscal years. Macquarie keeps an outperform rating and A$330.00 target price on the stock, which is up 1.0% at A$297.86. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL","LU1169590202.USD","SGXZ23171101.USD","BK4086","BK7501","BK7511","CSL.AU","LU1169589451.USD","BK7067","SG9999004303.SGD"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0451},{"period":"6month","weight":0.0878},{"period":"1year","weight":0.1445},{"period":"ytd","weight":0.0972}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}